Novo invests heavily in Danish manufacturing
The Danish diabetes giant, Novo Nordisk, is ready with a new large investment in its home country, which will create jobs in the town Kalundborg.
by Benjamin Werner Christensen
Novo Nordisk is now investing DKK 380 million (USD 67 million) in an overhaul of its manufacturing facilities in its factory in the Danish town Kalundborg, in order to produce a new type II diabetes drug, semaglutid, the company reveals.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
